ProSomnus SPAC Presentation Deck
ProSomnus Products Outperform the Competition
We believe that ProSomnus is the only OSA treatment solution that has scientifically demonstrated both American Academy of Sleep
Medicine ("AASM") and American Academy of Dental Sleep Medicine's ("AADSM") definitions of an effective OAT¹
EFFECTIVENESS
■ Effectiveness is a key driver of
treatment selection for physicians
and patients
■ The effectiveness advantage of
ProSomnus devices is a function
of:
- Significantly better adherence
rates
Strong efficacy rates
Superior Effectiveness2,3,4,5
ProSomnus
(Mild/Moderate)
ProSomnus
(All Severities)
CPAP
Upper Airway
Stimulation
1.
Legacy OAT
50%
48%
45%
85%
74%
PATIENT PREFERENCE
Patients are satisfied when their
symptoms are alleviated
■ Patients have been shown to
strongly favor ProSomnus devices
over alternatives
■ ProSomnus patient satisfaction
advantage is driven by comfort,
effectiveness and human factors
Superior Patient Satisfaction
Prefer ProSomnus over
my CPAP
Wear my ProSomnus
more than I wear my
CPAP
Find my ProSomnus
device easier to clean
than CPAP
Prefer ProSomnus over
my previous (legacy)
OAT
Mogell, K. et al. Definition of an Effective Oral Appliance for the Treatment of Obstructive Sleep Apnea and Snoring.
JDSM 6.3. 2019. Ramar, K et al. Clinical Practice Guideline for the Treatment of OSA. JCSM 11.7.2015
2. ProSomnus adherence: Stern, J. Efficacy and Effectiveness 2018 Jun; ProSomnus efficacy: Mosca et al. JCSM 2022;
18(3):911-919.
3. CPAP adherence and efficacy: Dieltjens M, et al. Oral Appliances in Obstructive Sleep Apnea 2019 Nov 8
4.
Upper Airway Stimulation Adherence: Thaler et al. Results of the ADHERE UAS Registry. Laryngoscope (130) 2020. UAS
Efficacy: Strollo, STAR Trial Group. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014 Jan 9
5. Legacy OAT adherence: Dieltjens M, et al. Objectively Measured vs. Self-Reported Compliance 2013 Nov; Legacy OAT
100%
100%
100%
100%
6.
7.
8.
9.
HEALTHCARE ECONOMICS
■ The cost of therapy is an
important consideration for
payors and healthcare providers
ProSomnus's cost advantages are
driven by low initial cost and few
remake issues
■
▪ Digital process enables ProSomnus
to produce a new device more
cost effectively than competitors
Lower Cost Per Day than Alternative
Therapy Devices7,8,9
ProSomnus OAT
CPAP
Legacy OAT
Neurostimulation
$1.30
$2.99
$3.23
$41.10
efficacy: Dieltjens M et al. Oral Appliances in OSA 2019 Nov
ProSomnus EVO IRB survey. AASM Scientific Abstract Presentation 2021.
2021 AADSM abstract
SIDE EFFECTS
Side effects are defined as events
that result in the discontinuation
of therapy, which lead to a
reduction in adherence and
ultimately effectiveness
▪ ProSomnus devices have been
engineered, based on specific
design inputs, to mitigate side
effects (short- and long-term)
Less Discontinuation of
Treatment Due to Side Effects 10,11,12
ProSomnus
OAT
PROSOMNUS
SLEEP TECHNOLOGIES
Neurostimulation
Legacy OAT
CPAP
Legacy OAT and neurostimulation cost per day based on internal management analyses
Measures cost of therapy as the quotient of the reimbursement cost and the warranty period for the device
ProSomnus Quality Management System Data, 2020
10.
11 Bestourous, Adverse events associated with the Inspire. Am J Otolaryngol. 2020 Jun 25
12. Ramar K, et al. Clinical practice guideline for the treatment of OSA. Journal of Dental Sleep Medicine 2015
0%
3%
5%
8%
28
STRICTLY CONFIDENTIALView entire presentation